Last updated: 2026-09-16 09:06:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Alkermes Inc. plc (ALKS) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $46.00, with a market capitalisation of $7.69B and a P/E ratio of 116.78. Over the past 52 weeks, its price has ranged from $26.50 to $55.67. This page covers its latest market performance, valuation, price trends and company information.
$7.69B | |
$45.01 | |
$80.71 | |
$5.55 | |
$46.03 | |
12.00 | |
1.89M | |
116.78 | |
$55.67 | |
$26.50 | |
-- | |
-- |
Alkermes Inc. plc (ALKS) is trading at $46.00 in pre-market trading as of 2026-09-16 08:57:00, down 0.07% ($0.03) from the previous close of $46.03
Pre-market trading shows how investors are pricing ALKS before the regular session opens. The current pre-market price is near the previous close, indicating cautious early trading sentiment.
Over the past seven days, Alkermes Inc. plc (ALKS) moved from $46.10 to $46.00, representing a decline of 0.23% ($0.10).
The stock traded between $44.63 and $46.93 during the period. The latest price is near the middle of the 7-day range, indicating range-bound.
The average daily volume was 1.50 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 66.8%
ALKS is currently trading at $46.00, placing it 66.8% of the way from its 52-week low of $26.50 to its 52-week high of $55.67. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 2050 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Alkermes Inc. plc (ALKS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.